The Helmholtz Centre for Infection Research (HZI) is organised in the form of a GmbH (equals “Ltd.”). Shareholders are the Federal Republic of Germany (90 percent) and the federal states Lower-Saxony (eight percent), Saarland (one percent) and Free State of Bavaria (one percent).

The shareholders' meeting, as the supreme management body of the HZI, meets at least once a year, takes the most important directional decisions, appoints the two managing directors and decides on their discharge. Representatives of the shareholders - together with experts from universities, clinics, industry, other research centres and the HZI itself - form the supervisory board. The HZI Supervisory Board meets twice a year, supervises the legality, expediency and economic efficiency of the management and decides on important research policy and financial matters of the company. The Scientific Committee provides the Supervisory Board with expert advice. The Centre's middle management consists of the heads of the scientific departments, the administrative units and the staff units.

Clinical Director

Markus Cornberg, MD is Professor of Medicine for Infectious disease with emphasis on hepatitis and attending physician in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School responsible for the infectious disease ward and the hepatitis outpatient clinic. In 2019 he was appointed Clinical Director of the HZI and Director of the Centre for Individualised Infection Medicine (CiiM). He is also the managing director of the German Competence Network for Viral Hepatitis (HepNet) and medical secretary of the German Liver Foundation.  

Markus Cornberg has a long-term interest in infectious diseases with a focus on viral liver diseases. In 2007, 2011 and in 2017 he coordinated the German consensus process for the management of hepatitis B. In 2012 he was the German representative in the panel for the EASL Practice Guidelines for Hepatitis B. Since 2017 he is member of the scientific committee and the governing board of EASL. He has published more than 150 scientific articles on viral hepatitis and serves as a reviewer for several journals such as the Lancet, Gastroenterology, Hepatology, GUT, and the Journal of Hepatology.

CV Markus Cornberg



PrintSend per emailShare